Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...

Novo Nordisk (NYSE: NVO) shareholders know all ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.

Novo Nordisk (NVO) is not concerned by the ongoing ... with a $2.5 billion API production site, and is building out the next step in the supply chain — a $4.1 billion fill-and-finish factory ...